Welcome to the Cannabis Countdown. In this week’s rendition, we’ll recap and countdown the top 10 Marijuana and Psychedelics industry news stories for the week of April 27th – May 3rd, 2020.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view full article.
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496) announced that it was selected as the headline partner for the Prohibition Partners LIVE ‘PSYCH: The Psychedelics Symposium‘ set to take place in June 2020. PSYCH is an event designed to bring together key figures and investors that are at the forefront of the emerging Psychedelics sector.
READ FULL CHAMPIGNON BRANDS ARTICLE
9. VIDEO: TCI Interviews Brad Rogers, CEO of Super State Operator Red White & Bloom
Rogers Shares His Thoughts on the Cannabis Industry as Well as His Vision for RWB Ahead of the Company’s Highly-Anticipated IPO
TCI host Alyssa Boston (Miss Universe Canada + Cannabis Crusader) recently sat down with Brad Rogers, CEO of Red White & Bloom (CSE: RWB | IPO May 2020). During the interview, Brad discusses a variety of topics including:
Meaning of ‘Super State Operator’
RWB’s Strategy Behind Staying Private Until Now
Assessment of the Market and Top MSOs Like Trulieve (CSE: TRUL) (OTCQX: TCNNF)
Revenue Opportunities (USA v CDN)
What Investors Can Expect from RWB Moving Forward in 2020 + Much More...
WATCH FULL RWB CEO INTERVIEW
8. Silicon Valley Billionaire Peter Thiel Backs Psychedelics Firm ATAI in Million Funding Round
ATAI is Said to Be Working Towards an IPO, Which Could Take Place Within the Next 12 Months
A new group of renowned investors led by PayPal co-founder Peter Thiel took a position in Psychedelics startup ATAI Life Sciences. ATAI says it plans to use the proceeds from its $24 million convertible note financing to explore the effects of Psychedelic Medicine on mental health.
READ FULL ATAI LIFE SCIENCES ARTICLE
7. How to Understand CBD Lingo
Today, CBD is on Everyone’s Lips, Dominating the Conversation on Medical Cannabis
CBD, or cannabidiol, is a non-euphoric cannabinoid found in both hemp and high-THC cannabis. Knowing the difference between broad-spectrum, full-spectrum and isolate — as well as CBD oil and hemp seed oil — can help you choose the products that are right for you.
READ FULL CBD LINGO ARTICLE
6. UK Psychedelics Firm Secures Million to Ramp Up Study of Magic Mushrooms on Depression
In 2018, Compass Received FDA Breakthrough Therapy Designation for its Psilocybin Therapy
Compass Pathways, a UK-based Psychedelics company focused on mental health care, recently announced the successful close of its $80 million Series B funding round. The firm says it plans to use the capital infusion to expand the development of its Psilocybin therapy for treatment-resistant depression program.
READ FULL COMPASS PATHWAYS ARTICLE HERE
5. CIBC Reduces Cannabis Sales Forecast for 2020
Prior to the Coronavirus Pandemic, CIBC Had Initially Estimated Cannabis Sales to Hit .4 Billion
One of Canada’s main banking subsidiaries, CIBC Capital Markets, has reduced its adult-use cannabis forecast for 2020 to $2.5 billion. The predicted decrease in recreational cannabis sales stems from a slow roll-out of retail stores in several significant provinces, in addition to the closing of store locations across the country amid the coronavirus pandemic.
READ FULL CIBC CANNABIS ARTICLE
4. What You Need to Know About MindMed’s Bad LSD Trip ‘Off-Switch’
The Company Announced it Has Discovered and Filed a Patent Application for a Neutralizing Agent Intended to Stop the Effects of LSD
Psychedelic pharmaceutical company MindMed (NEO: MMED) (OTCQB: MMEDF) (FRA: BGHM) says it found an off-switch to end a bad LSD trip.
READ FULL MINDMED ARTICLE
3. Trump Admin Could Let Researchers Study Marijuana Dispensary Products, Scientist Argues After DOJ Memo Released
They Want Lawmakers’ Help Pressuring the Trump Administration to Take Advantage of a Process They Say Would Not Necessarily Violate International Treaties
A scientist in a case that forced the release of a previously “secret” Justice Department document about federally authorized marijuana research this week is now calling on Congress to urge administrative action to more rapidly expand studies into the therapeutic potential of cannabis.
READ FULL CANNABIS RESEARCH ARTICLE
2. Hollister Biosciences Closes Acquisition of Psychedelics Company AlphaMind
The AlphaMind Acquisition is a Milestone Moment for the Rapidly Ascending Cannabis Company
Hollister Biosciences (CSE: HOLL) (OTC: HSTRF) (FRA: HOB) announced on Thursday the close of its acquisition of AlphaMind Brands, following the recently signed definitive agreement. With the transformational deal now complete, Hollister has officially diversified into the flourishing world of Psychedelics.
READ FULL HOLLISTER ARTICLE
1. Investors are Jumping Into Psychedelics After Learning Hard Lessons in the Cannabis Industry
Some Insiders Say the Psychedelics Industry Could Be as Much as Billion Annually
Research suggests that psychedelics are catching on. The psychedelic sector is going to be one of the drivers of the collective recovery from the current economic malaise around the world, according to Richard Skaife, a venture capitalist with The Conscious Fund.
READ FULL PSYCHEDELICS ARTICLE
Image sourced from Unsplash
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.